{
    "id": 3842,
    "fullName": "PIK3CA H1047Y",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "PIK3CA H1047Y is a hotspot mutation that lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). H1047Y confers a gain of function on the Pik3ca protein as indicated by increased phosphorylation of Akt, activation of downstream signaling, and is transforming in cell culture (PMID: 17376864, PMID: 29533785).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 101,
                    "pubMedId": 17376864,
                    "title": "Rare cancer-specific mutations in PIK3CA show gain of function.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17376864"
                },
                {
                    "id": 11238,
                    "pubMedId": 29533785,
                    "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5290,
        "geneSymbol": "PIK3CA",
        "terms": [
            "PIK3CA",
            "CLAPO",
            "CLOVE",
            "CWS5",
            "MCAP",
            "MCM",
            "MCMTC",
            "p110-alpha",
            "PI3K",
            "PI3K-alpha"
        ]
    },
    "variant": "H1047Y",
    "createDate": "03/18/2015",
    "updateDate": "04/29/2018",
    "referenceTranscriptCoordinates": {
        "id": 171867,
        "transcript": "NM_006218",
        "gDna": "chr3:g.179234296C>T",
        "cDna": "c.3139C>T",
        "protein": "p.H1047Y",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5181,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, glioblastoma cell lines harboring PIK3CA H1047Y demonstrated increased sensitivity to YM-204 induced growth inhibition (PMID: 24718026).",
            "molecularProfile": {
                "id": 3652,
                "profileName": "PIK3CA H1047Y"
            },
            "therapy": {
                "id": 2967,
                "therapyName": "YM-024",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4902,
                    "pubMedId": 24718026,
                    "title": "Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24718026"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2947,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CH5132799 inhibited cell growth in a human endometrial cancer cell line harboring a PIK3CA H1047Y mutation, and inhibited tumor growth in xenograft models (PMID: 21558396).",
            "molecularProfile": {
                "id": 3652,
                "profileName": "PIK3CA H1047Y"
            },
            "therapy": {
                "id": 2152,
                "therapyName": "CH5132799",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1985,
                    "pubMedId": 21558396,
                    "title": "The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21558396"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10541,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring KRAS G13C, PIK3CA H1047Y, PTEN G143fs, and PTEN K267fs was sensitive to treatment with DS-7423, demonstrating inhibition of cell proliferation in culture and tumor growth inhibition in xenograft models (PMID: 24504419).",
            "molecularProfile": {
                "id": 27593,
                "profileName": "KRAS G13C PIK3CA H1047Y PTEN G143fs PTEN K267fs"
            },
            "therapy": {
                "id": 722,
                "therapyName": "DS-7423",
                "synonyms": null
            },
            "indication": {
                "id": 5304,
                "name": "ovarian clear cell adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4912,
                    "pubMedId": 24504419,
                    "title": "Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24504419"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17135,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA H1047Y (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34227,
                "profileName": "ESR1 pos PIK3CA H1047Y"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19581,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (SOLAR-1) that supported FDA approval, Piqray (Alpelisib) and Faslodex (fulvestrant) combination treatment resulted in improved median progression-free survival (11 vs 5.7 mo, HR=0.65, p<0.001) compared to Faslodex (fulvestrant) plus placebo in patients with advanced hormone-receptor positive, Erbb2 (Her2) negative breast cancer who had prior endocrine therapy and harboring PIK3CA mutations as detected by an FDA-approved test, including PIK3CA H1047Y (PMID: 31091374; NCT02437318).",
            "molecularProfile": {
                "id": 34237,
                "profileName": "PGR pos PIK3CA H1047Y"
            },
            "therapy": {
                "id": 5929,
                "therapyName": "Alpelisib + Fulvestrant",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15176,
                    "pubMedId": 31091374,
                    "title": "Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31091374"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15447,
                    "pubMedId": null,
                    "title": "Piqray (alpelisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3652,
            "profileName": "PIK3CA H1047Y",
            "profileTreatmentApproaches": [
                {
                    "id": 17235,
                    "name": "Akt2 Inhibitor",
                    "profileName": "PIK3CA H1047Y"
                },
                {
                    "id": 17233,
                    "name": "PIK3CA inhibitor",
                    "profileName": "PIK3CA H1047Y"
                },
                {
                    "id": 17238,
                    "name": "Akt Inhibitor (Pan)",
                    "profileName": "PIK3CA H1047Y"
                },
                {
                    "id": 17232,
                    "name": "Akt1 Inhibitor",
                    "profileName": "PIK3CA H1047Y"
                },
                {
                    "id": 17231,
                    "name": "mTORC1 Inhibitor",
                    "profileName": "PIK3CA H1047Y"
                },
                {
                    "id": 17234,
                    "name": "mTORC2 Inhibitor",
                    "profileName": "PIK3CA H1047Y"
                },
                {
                    "id": 17237,
                    "name": "mTOR Inhibitor",
                    "profileName": "PIK3CA H1047Y"
                },
                {
                    "id": 17236,
                    "name": "PI3K Inhibitor (Pan)",
                    "profileName": "PIK3CA H1047Y"
                }
            ]
        },
        {
            "id": 27593,
            "profileName": "KRAS G13C PIK3CA H1047Y PTEN G143fs PTEN K267fs",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34227,
            "profileName": "ESR1 pos PIK3CA H1047Y",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34237,
            "profileName": "PGR pos PIK3CA H1047Y",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 171866,
            "transcript": "XM_006713658",
            "gDna": "chr3:g.179234296C>T",
            "cDna": "c.3139C>T",
            "protein": "p.H1047Y",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 171868,
            "transcript": "XM_011512894",
            "gDna": "chr3:g.179234296C>T",
            "cDna": "c.3139C>T",
            "protein": "p.H1047Y",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 171867,
            "transcript": "NM_006218",
            "gDna": "chr3:g.179234296C>T",
            "cDna": "c.3139C>T",
            "protein": "p.H1047Y",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}